ARIAD's Leukemia Drug Iclusig Gets Full Approval In U.S.
Zacks Investment Research | Nov 29, 2016 10:03PM ET
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on the receipt of accelerated approval in Dec 2012.
Iclusig is approved for the treatment of adult patients suffering from T315I-positive chronic myeloid leukemia (CML: chronic, accelerated or blast phase) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) or for whom no other TKI therapy is approved.
Over the last one month, ARIAD’s share price has surged 58.3% compared to the Zacks classified Drugs Market of 7.6%. We expect shares to gain higher following the latest approval.
Note that Iclusig, ARIAD’s only marketed drug, is approved in both the U.S. and the EU. The latest approval and label update was based on long-term safety and efficacy data from the pivotal phase II PACE clinical trial (n=449) on Iclusig in heavily pretreated patients with resistant or intolerant CML or Ph+ ALL. Data from the PACE study showed that a minimum follow-up of 48 months with Iclusig led to sustained long-term cytogenetic and molecular responses in many chronic-phase CML patients.
The four-year follow-up data demonstrated the durability of the high response rates achieved with Iclusig in refractory CML patients for whom no other TKI therapy is appropriate, including those with the T315I mutation.
Notably, Iclusig was granted orphan drug designation by the FDA for the treatment of leukemia.
This September, Iclusig received Japanese approval for the treatment of CML and is being marketed by partner Otsuka.
Apart from the PACE study, ARIAD is conducting two other studies on Iclusig – the OPTIC dose-ranging study and the OPTIC-2L study for second-line chronic-phase CML.
Even though the CML market represents significant potential, Iclusig faces intense competition, as the market is crowded by Novartis AG’ (NYSE:NVS) Gleevec, Bristol-Myers Squibb Company’s (NYSE:BMY) Sprycel and Pfizer Inc.’s (NYSE:PFE) Bosulif among others. All the three drugs are approved for the treatment of CML in patients who are either resistant or intolerant to prior TKI therapies.
ARIAD PHARMA Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.